All In Biotech

Drug Trial Radar · NCT01396291

Efficacy and Safety of Asenapine in the Prevention of Recurrence of Mood Episodes in Participants With Bipolar 1 Disorder (P06384)

A Double-Blind, Placebo-Controlled Trial of Asenapine in the Prevention of Recurrence of a Mood Episode After Stabilization of an Acute Manic/Mixed Episode in Subjects With Bipolar 1 Disorder (Phase 3B, Protocol P06384)

Last checked: Nov 20, 2026Latest source record: Dec 4, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 561 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

561

Actual

Start

Dec 2011

Primary completion

Apr 2015

Study completion Jun 2015

Sponsor

Lead sponsor
Forest LaboratoriesAbbVie (ABBV)
Sponsor type
Industry
First posted
Jul 18, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being done to evaluate the efficacy and safety of asenapine as compared to placebo in preventing the recurrence of mood episodes after stabilization of an acute/manic mixed episode in participants with Bipolar 1 Disorder. After a Screening Period, each participant will receive open-label asenapine and matching placebo for 12 to 16 weeks. Participants who meet stabilization criteria may then be randomized into one of the two study arms (asenapine or matching placebo) to receive double-blind treatment for up to an additional 26-weeks.

Conditions

  • Bipolar 1 Disorder

Interventions

  • asenapineDrug

    asenapine, sublingual tablets, 5 to 10 mg twice per day (BID)

  • placeboDrug

    asenapine-matched placebo, sublingual tablets, BID

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The time (in days) to recurrence of any mood event during the double-blind treatment periodTime frame: From Week 12 or 16 to Week 38 or 42

Locations

80 sites in 10 countries. Site status is shown where the registry gives one.

  • Forest Investigative Site 3017

    Anaheim, California

  • Forest Investigative Site 3019

    Chino, California

  • Forest Investigative Site 3001

    Escondido, California

  • Forest Investigative Site 3004

    National City, California

  • Forest Investigative Site 3006

    Oakland, California

  • Forest Investigative Site 3003

    Orange, California

  • Forest Investigative Site 3007

    Torrance, California

  • Forest Investigative Site 3042

    Colorado Springs, Colorado

  • Forest Investigative Site 3012

    Jacksonville, Florida

  • Forest Investigative Site 3040

    Kissimmee, Florida

  • Forest Investigative Site 3031

    Leesburg, Florida

  • Forest Investigative Site 3015

    Miami, Florida

  • Forest Investigative Site 3010

    Tampa, Florida

  • Forest Investigative Site 3039

    Atlanta, Georgia

  • Forest Investigative Site 3032

    Chicago, Illinois

  • Forest Investigative Site 3029

    Schaumburg, Illinois

  • Forest Investigative Site 3021

    Witchita, Kansas

  • Forest Investigative Site 3014

    Gladstone, Missouri

  • Forest Investigative Site 3002

    Albuquerque, New Mexico

  • Forest Investigative Site 3024

    Elmsford, New York

  • Forest Investigative Site 3037

    Avon Lake, Ohio

  • Forest Investigative Site 3041

    Cincinnati, Ohio

  • Forest Investigative Site 3023

    Oklahoma City, Oklahoma

  • Forest Investigative Site 3035

    Oklahoma City, Oklahoma

  • Forest Investigative Site 3033

    Memphis, Tennessee

  • Forest Investigative Site 3009

    Houston, Texas

  • Forest Investigative Site 3020

    Houston, Texas

  • Forest Investigative Site 3036

    Irving, Texas

  • Forest Investigative Site 3027

    Plano, Texas

  • Forest Investigative Site 3000

    Wichita Falls, Texas

  • Forest Investigative Site 3102

    Burgas, Bulgaria

  • Forest Investigative Site 3103

    Varna, Bulgaria

  • Forest Investigative Site 3105

    Pleven, Pleven, Bulgaria

  • Forest Investigative Site 3104

    Sofia, Sofia-Grad, Bulgaria

  • Forest Investigative Site 3100

    Sofia, Sofia-Grad, Bulgaria

  • Forest Investigative Site 3106

    Sofia, Sofia-Grad, Bulgaria

  • Forest Investigative Site 3101

    Varna, Varna, Bulgaria

  • Forest Investigative Site 3153

    Zagreb, City of Zagreb, Croatia

  • Forest Investigative Site 3154

    Zagreb, City of Zagreb, Croatia

  • Forest Investigative Site 3152

    Zagreb, City of Zagreb, Croatia

Showing 40 of 80 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.